Gilead Stock News

Gilead Sciences on Monday said a late-stage trial of its antibody-drug conjugate Trodelvy failed to show that it significantly improved survival for previously treated patients with advanced non-small

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.

Jenny Harrington, Gilman Hill Asset Management CEO, Jim Lebenthal, chief equity strategist at Cerity Partners, Joe Terranova, senior managing director at Virtus Investment Partners, and Rob Sechan, ma

In a downtown Toronto skyscraper one block away from the Hockey Hall of Fame, a small hedge fund is hoping it has found an edge in financial markets. Castle Ridge Asset Management is betting on Wallac

Two sets of reliable stock market cycles have topped. Technically, the market does not appear as weak as expected.

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $85.39, denoting a +1.05% change from the preceding trading day.

Every day for the next three weeks, we're going to highlight one of Schaeffer's top 12 picks for 2024.

Biotechnology company Gilead Sciences (NASDAQ: GILD ) wasn't a “Magnificent Seven” company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024.

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

This article introduces a dividend stock selection process called YARP (Yield At a Reasonable Price) that prioritizes risk management and total return. YARP aims to identify stocks with historically h

Up 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It's very early, but the sector has outpaced all other 10 economic groups since

Gilead Sciences CEO Daniel O'Day joins 'Squawk Box' to discuss Gilead's drug pipeline in 2024, the company's HIV treatment, breast cancer drug, and more.

The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventi

In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.

Gilead Sciences is recovering from reduced Veklury (remdesivir) revenue following the height of the COVID-19 pandemic. The company, however, is making progress in HIV product sales and oncology, the l